FDA Committee Recommends Adding Six Peptides to Compounding List

The FDA Pharmacy Compounding Advisory Committee voted during its July 23-24, 2026 meeting to recommend adding six out of seven reviewed peptides to the 503A bulk drug compounding list, a regulatory shift that will eventually expand legal clinic access to popular therapies if finalized. Along with BPC-157 and TB-500, the committee recommended KPV, MOTs-C, Semax, and Epitalon. It rejected only Emideltide, which is also known as delta sleep-inducing peptide. While this is a major regulatory signal, it does not change your daily purchasing yet. The committee's recommendations are nonbinding, meaning compounding these peptides remains illegal under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act until the FDA completes a formal rulemaking process or Congress amends the statute. While FDA scientists argue these peptides present safety risks, Health and Human Services Secretary Robert F. Kennedy Jr. supports making them more available. For now, you must keep these compounded peptides off your clinic shelves to avoid compliance risks, but prepare your treatment menus for their potential legal entry down the road.

Source: Holland & Knight, https://www.hklaw.com/en/insights/publications/2026/08/fda-advisory-committee-endorses-compounding-of-certain-peptides